Skip to main content
. 2021 Dec 1;13(1):107–116. doi: 10.1111/1759-7714.14232

FIGURE 1.

FIGURE 1

(a) Waterfall plots for patients with target lesions during treatment with crizotinib (n = 42). (b) Extent of tumor reduction during treatment with crizotinib (n = 42). (c) Waterfall plots for patients with target lesions during treatment with alectinib. (d) Extent of tumor reduction during treatment with alecitnib (n = 46)